BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 11867687)

  • 21. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
    Bouzar AB; Boxus M; Defoiche J; Berchem G; Macallan D; Pettengell R; Willis F; Burny A; Lagneaux L; Bron D; Chatelain B; Chatelain C; Willems L
    Br J Haematol; 2009 Jan; 144(1):41-52. PubMed ID: 19006566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells.
    Moon EY; Lerner A
    Cancer Res; 2002 Oct; 62(20):5711-9. PubMed ID: 12384529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
    Scamardella F; Maconi M; Albertazzi L; Gamberi B; Gugliotta L; Brini M
    Lab Hematol; 2006; 12(4):187-92. PubMed ID: 17118768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
    Johnston JB; Kabore AF; Strutinsky J; Hu X; Paul JT; Kropp DM; Kuschak B; Begleiter A; Gibson SB
    Oncogene; 2003 Nov; 22(51):8356-69. PubMed ID: 14614459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
    Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
    Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia.
    Morabito F; Filangeri M; Sculli G; Oliva B
    Haematologica; 1998 Nov; 83(11):1046-8. PubMed ID: 9864930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R; Kitada S; Flinn IW; Pearson M; Young D; Reed JC; Byrd JC
    J Clin Oncol; 2003 Apr; 21(8):1466-71. PubMed ID: 12697868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bcl-2 regulatory pathway is functional in chronic lymphocytic leukemia.
    Goolsby C; Paniagua M; Tallman M; Gartenhaus RB
    Cytometry B Clin Cytom; 2005 Jan; 63(1):36-46. PubMed ID: 15624202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells.
    Sanz L; Garcia-Marco JA; Casanova B; de La Fuente MT; García-Gila M; Garcia-Pardo A; Silva A
    Biochem Biophys Res Commun; 2004 Mar; 315(3):562-7. PubMed ID: 14975737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
    Morabito F; Mangiola M; Rapezzi D; Zupo S; Oliva BM; Ferraris AM; Spriano M; Rossi E; Stelitano C; Callea V; Cutrona G; Ferrarini M
    Haematologica; 2003 Aug; 88(8):864-73. PubMed ID: 12935974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.
    Fernández Calotti P; Galmarini CM; Cañones C; Gamberale R; Saénz D; Avalos JS; Chianelli M; Rosenstein R; Giordano M
    Biochem Pharmacol; 2008 Feb; 75(4):857-65. PubMed ID: 18078872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Apoptosis in chronic lymphocytic leukemia].
    Giordano M
    Medicina (B Aires); 2000; 60 Suppl 2():12-6. PubMed ID: 11188924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.
    Citores MJ; Castejon R; Villarreal M; Rosado S; Garcia-Marco JA; Vargas JA
    Exp Hematol; 2010 Mar; 38(3):165-73. PubMed ID: 20026377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
    Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
    Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
    Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
    Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.
    Olsson A; Norberg M; Okvist A; Derkow K; Choudhury A; Tobin G; Celsing F; Osterborg A; Rosenquist R; Jondal M; Osorio LM
    Br J Cancer; 2007 Sep; 97(6):769-77. PubMed ID: 17726463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
    Zhong Y; Bakke AC; Fan G; Braziel RM; Gatter KM; Leis JF; Maziarz RT; Huang JZ
    Cytometry B Clin Cytom; 2007 May; 72(3):189-95. PubMed ID: 17226861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
    de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
    Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
    Rogalinska M; Goralski P; Wozniak K; Bednarek JD; Blonski JZ; Robak T; Piekarski H; Hanausek M; Walaszek Z; Kilianska ZM
    Leuk Res; 2009 Feb; 33(2):308-14. PubMed ID: 18676014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.